Olav Fromm, managing director of Chiesi Nordics, explains the deep roots of Chiesi in Sweden, where its blockbuster drug, a surfactant for treating neonatal babies, was developed. He also touches upon the strategic importance of the region to Chiesi, with the recent creation of a fully-fledged Nordic subsidiary, which will house the group's rare diseases research and development. Fromm then delves into the complexities of the Swedish regionalised healthcare system and shares his priorities going forward to further develop Chiesi's footprint in the region.
The creation of Chiesi Nordics in 2014 marked the dawn of a new era for the group in the region
